drugset / Trial / NCT02124668
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Phase 2
Completed
30 enrolled
Astellas Pharma Europe B.V.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to monitor the safety of enzalutamide in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
Timeline
- Start
- 2014-09-23
- Primary completion
- 2017-05-25
- Completion
- 2017-05-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | — | Oral |